Management of malignant pleural effusions
- PMID: 15182263
- DOI: 10.1111/j.1440-1843.2004.00566.x
Management of malignant pleural effusions
Abstract
Malignant pleural effusion is a common clinical problem. Evacuation of the pleural fluid and prevention of its reaccumulation are the main aims of management. Pleurodesis should be attempted early, although considerable practice variations exist in the way it is performed. There is a lack of consensus among respiratory physicians worldwide on the optimal method and agent for pleurodesis. Talc remains the most commonly used pleurodesing compound in most countries. While talc produces a higher success rate than other compounds, it generates more side-effects. The association between talc and ARDS continues to be debated. Ambulatory small-bore pleural catheter drainage followed by intrapleural instillation of a pleurodesing agent is increasingly accepted as an alternative to conventional in-patient pleurodesis. Development of novel methods to control pleural fluid formation should be made a high priority in future pleural research.
Similar articles
-
Malignant pleural effusion, current and evolving approaches for its diagnosis and management.Lung Cancer. 2006 Oct;54(1):1-9. doi: 10.1016/j.lungcan.2006.04.016. Epub 2006 Aug 7. Lung Cancer. 2006. PMID: 16893591 Review.
-
Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions.J BUON. 2006 Oct-Dec;11(4):463-7. J BUON. 2006. PMID: 17309178
-
Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.Eur J Cardiothorac Surg. 2006 Dec;30(6):827-32. doi: 10.1016/j.ejcts.2006.10.002. Eur J Cardiothorac Surg. 2006. PMID: 17113008 Clinical Trial.
-
[Treatment of malignant pleural effusion by pleurodesis with talc].Chir Ital. 2000 Sep-Oct;52(5):541-7. Chir Ital. 2000. PMID: 11190547 Italian.
-
Pleurodesis for malignant pleural effusions: current controversies and variations in practices.Curr Opin Pulm Med. 2004 Jul;10(4):305-10. doi: 10.1097/01.mcp.0000129756.87090.55. Curr Opin Pulm Med. 2004. PMID: 15220757 Review.
Cited by
-
Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.Oncoimmunology. 2019 Nov 3;9(1):1684713. doi: 10.1080/2162402X.2019.1684713. eCollection 2020. Oncoimmunology. 2019. PMID: 32002298 Free PMC article.
-
Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.Oncol Lett. 2017 Dec;14(6):7931-7940. doi: 10.3892/ol.2017.7195. Epub 2017 Oct 16. Oncol Lett. 2017. PMID: 29250182 Free PMC article.
-
Pleural effusion: diagnosis, treatment, and management.Open Access Emerg Med. 2012 Jun 22;4:31-52. doi: 10.2147/OAEM.S29942. eCollection 2012. Open Access Emerg Med. 2012. PMID: 27147861 Free PMC article. Review.
-
Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings.PLoS One. 2012;7(12):e49894. doi: 10.1371/journal.pone.0049894. Epub 2012 Dec 12. PLoS One. 2012. PMID: 23251353 Free PMC article.
-
Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.Ann Thorac Cardiovasc Surg. 2016;22(1):20-6. doi: 10.5761/atcs.oa.15-00230. Epub 2015 Dec 4. Ann Thorac Cardiovasc Surg. 2016. PMID: 26639937 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources